AIMS: Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease. As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular protection to Hp 2-2 DM individuals. MATERIALS & METHODS: We determined the Hp genotype on DM participants from two trials (HOPE and ICARE) and assessed the effect of vitamin E by Hp genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and cardiovascular death. Data was analyzed with a fixed-effect model. These results were input into a simulation model, the Evidence Based Medicine Integrator, in order to estimate their long-term implications in a real-world population from Kaiser Permanente (CA, USA). RESULTS: Meta-analysis of the two trials demonstrated a significant overall reduction in the composite end point in Hp 2-2 DM individuals with vitamin E (odds ratio: 0.58; 95% CI: 0.40-0.86; p = 0.006). There was a statistically significant interaction between the Hp genotype and vitamin E on the composite end point. In these trials, Hp typing of 69 DM individuals and treating those with the Hp 2-2 with vitamin E prevented one myocardial infarct, stroke or cardiovascular death. Lifelong administration of vitamin E to Hp 2-2 DM individuals in the Kaiser population would increase their life expectancy by 3 years. CONCLUSION: A pharmacogenomic strategy of screening DM individuals for the Hp genotype and treating those with Hp 2-2 with vitamin E appears to be highly clinically effective.
AIMS: Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease. As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular protection to Hp 2-2 DM individuals. MATERIALS & METHODS: We determined the Hp genotype on DMparticipants from two trials (HOPE and ICARE) and assessed the effect of vitamin E by Hp genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and cardiovascular death. Data was analyzed with a fixed-effect model. These results were input into a simulation model, the Evidence Based Medicine Integrator, in order to estimate their long-term implications in a real-world population from Kaiser Permanente (CA, USA). RESULTS: Meta-analysis of the two trials demonstrated a significant overall reduction in the composite end point in Hp 2-2 DM individuals with vitamin E (odds ratio: 0.58; 95% CI: 0.40-0.86; p = 0.006). There was a statistically significant interaction between the Hp genotype and vitamin E on the composite end point. In these trials, Hp typing of 69 DM individuals and treating those with the Hp 2-2 with vitamin E prevented one myocardial infarct, stroke or cardiovascular death. Lifelong administration of vitamin E to Hp 2-2 DM individuals in the Kaiser population would increase their life expectancy by 3 years. CONCLUSION: A pharmacogenomic strategy of screening DM individuals for the Hp genotype and treating those with Hp 2-2 with vitamin E appears to be highly clinically effective.
Authors: Ariel Roguin; Werner Koch; Adnan Kastrati; Doron Aronson; Albert Schomig; Andrew P Levy Journal: Diabetes Care Date: 2003-09 Impact factor: 19.112
Authors: Dan Farbstein; Shany Blum; Mordechai Pollak; Roy Asaf; Hilla Lee Viener; Orit Lache; Rabea Asleh; Rachel Miller-Lotan; Ido Barkay; Michael Star; Avery Schwartz; Shiri Kalet-Littman; David Ozeri; Jacob Vaya; Hagai Tavori; Moshe Vardi; Arie Laor; Stephen E Bucher; Yefim Anbinder; Doron Moskovich; Nur Abbas; Netta Perry; Yishai Levy; Andrew P Levy Journal: Atherosclerosis Date: 2011-06-13 Impact factor: 5.162
Authors: Bubu A Banini; Sophie C Cazanave; Katherine P Yates; Amon Asgharpour; Robert Vincent; Faridoddin Mirshahi; Peter Le; Melissa J Contos; James Tonascia; Naga P Chalasani; Kris V Kowdley; Arthur J McCullough; Cynthia A Behling; Jeffrey B Schwimmer; Joel E Lavine; Arun J Sanyal Journal: J Clin Gastroenterol Date: 2019 Nov/Dec Impact factor: 3.062
Authors: Nina S Levy; Moshe Vardi; Shany Blum; Rachel Miller-Lotan; Yefim Afinbinder; Patricia A Cleary; Andrew D Paterson; Bhupinder Bharaj; Janet K Snell-Bergeon; Marian J Rewers; Orit Lache; Andrew P Levy Journal: Clin Chem Lab Med Date: 2013-08 Impact factor: 3.694
Authors: Rabea Asleh; Farid M Nakhoul; Rachel Miller-Lotan; Hoda Awad; Dan Farbstein; Nina S Levy; Nakhoul Nakhoul; Theodore C Iancu; Irena Manov; Michael Laue; Maret G Traber; Katie M Lebold; Andrew P Levy Journal: Free Radic Biol Med Date: 2012-06-27 Impact factor: 7.376